Option chain shows key data for Daiichi Sankyo Co's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Daiichi Sankyo Co.

Daiichi Sankyo Co (OTC:DSNKY) Stock, Option Chain

DAIICHI SANKYO

Daiichi Sankyo Co

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

FDA Shutterstock

Biotech

Large Cap

News

Health Care

General

DSKYF

DSNKY

FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant efficacy in the DESTINY-Breast06 trial.

FDA Approves AstraZeneca, Daiichi Sankyo&#39;s Enhertu For Certain Type Of Breast Cancer Patients

cancer

Equities

Movers

Trading Ideas

AstraZeneca&#39;s Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies, based on Phase 3 trial data.

FDA Approves AstraZeneca&#39;s Datroway For Pretreated Breast Cancer Patients

astrazeneca

AstraZeneca&#39;s Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression outcomes in treated patients.

After Lung Cancer Approval, AstraZeneca&#39;s Imfinzi Goes Under FDA Priority Review For Bladder Cancer

DAIICHI SANKYO S/ADR by Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Co Ltd

Press Releases

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology

GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

CGEN

GRAL

TYO:4568

Comments

Daiichi Sankyo Co

Daiichi Sankyo Co (DSNKY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga